

Table I. *Studies addressing the impact of HA-PCI.*

Study	Number of patients	Type of study	Objective/Primary endpoint	Objective/Primary endpoint achieved	Neurocognitive test	Follow up assessment (months)
Kundapur <i>et al.</i> (16)	70	Retrospective	Safety profile	Yes	N/A	N/A
Redmond <i>et al.</i> (17)	20	Prospective	Neurocognitive benefit	Yes	HVLT-R	6
Dios <i>et al.</i> (19)	118	Phase III RCT	Neurocognitive benefit	Yes	FCSRT	3, 6, 12, 24
Belderbos <i>et al.</i> (20)	168	Phase III RCT	Neurocognitive benefit	No	HVLT – R	4
Chammah <i>et al.</i> (22)	22	Retrospective	Effect on metabolic FDG activity (PET)	Yes	N/A	up to 13
Mayinger <i>et al.</i> (23)	18	Retrospective	Effect on white matter changes (MRI)	No	N/A	7
Gui <i>et al.</i> (24)	22	Secondary analysis of prospective trial	Effect on brain volume (MRI)/neurocognition	No	HVLT-R	6
Vees <i>et al.</i> (21)	38	Phase II	Neurocognitive effect of concurrent chemo/HA-PCI	Yes	HVLT – R	1, 6, 12

RCT: Randomised control trial; FDG: Fluorodeoxyglucose; PET: positron emission tomography; MRI: magnetic resonance imaging; HA-PCI: hippocampal avoidance – prophylactic cranial irradiation; HVLT-R: Hopkins verbal learning test-revised; FCSRT: free and cued selective reminding test; N/A: not applicable.